^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

E3 ubiquitin-ligase hakai inhibitor

Related drugs:
2years
Role of the E3 ubiquitin-ligase Hakai in intestinal inflammation and cancer bowel disease. (PubMed, Sci Rep)
In conclusion, Hakai regulates FASN ubiquitination and degradation, resulting in the regulation of FASN-mediated lipid accumulation, which is associated to the development of inflammatory bowel disease. The interaction between Hakai and FASN may be an important mechanism for the homeostasis of intestinal barrier function and in the pathogenesis of this disease.
Journal
|
CDH1 (Cadherin 1) • FAS (Fas cell surface death receptor) • FASN (Fatty acid synthase)
|
CDH1 expression